American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Karyopharm Therapeutics Inc. (KPTI)

$0.52 -5.24% NASDAQ: KPTI · 15-min delayed

NEWTON, Massachusetts
Public · NASDAQ: KPTI
228 employees

Visit website Follow

$167.9MMarket cap

$146.1MRevenue · FY2025

-$196.0MNet income

228Employees

KPTINASDAQ

2013IPO

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: KPTI
Employees: 228
IPO date: Nov 6, 2013
Headquarters: 85 WELLS AVENUE
NEWTON, Massachusetts 02459
Phone: 617-658-0600
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 549300J1VANRCNTYST87

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: KPTI Nasdaq
SEC CIK: 1503802
LEI: 549300J1VANRCNTYST87
EIN: 263931704
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Karyopharm Therapeutics Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/karyopharm-therapeutics-inc/"><img src="https://americancompanies.com/badge/karyopharm-therapeutics-inc.svg" alt="Karyopharm Therapeutics Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Karyopharm Therapeutics Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $146.1M
Net income: -$196.0M
Total assets: $108.4M
Market cap: $167.9M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: KPTI

$0.52 -5.24%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.32 $10.67

52-week range

Market cap: $167.9M
Shares outstanding: 322.9M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Nov 6, 2013

Karyopharm Therapeutics Inc. (KPTI) Stock Price

Reported a net loss of $196.0M in FY2025.
Trading 95% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Karyopharm Therapeutics Inc..

Write a review

Newsroom

News about Karyopharm Therapeutics Inc.

Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight GlobeNewswire Inc. · 2026-09-03 · positive INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI GlobeNewswire Inc. · 2026-08-04 · negative Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress GlobeNewswire Inc. · 2026-06-14 · positive International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month GlobeNewswire Inc. · 2025-03-01 · positive Glioblastoma Multiforme Treatment Market Size to Reach USD 5.68 Bn by 2033 GlobeNewswire Inc. · 2024-11-25 · positive Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround Benzinga · 2024-09-05 · positive

News & sentiment via Polygon.io

FAQ

Karyopharm Therapeutics Inc.: frequently asked questions

Is Karyopharm Therapeutics Inc. an American company?

Karyopharm Therapeutics Inc. is a US-based company headquartered in Newton, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Karyopharm Therapeutics Inc. headquartered?

Karyopharm Therapeutics Inc. is headquartered in Newton, Massachusetts, United States.

Is Karyopharm Therapeutics Inc. publicly traded?

Yes — Karyopharm Therapeutics Inc. is a publicly traded company. Its stock trades under the ticker symbol KPTI on the NASDAQ.

What does Karyopharm Therapeutics Inc. do?

Karyopharm Therapeutics Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore